SEARCH

SEARCH BY CITATION

References

  • 1
    Horton R. GBD 2010: understanding disease, injury, and risk. Lancet. 2013;380:20532054.
  • 2
    Das P, Samarasekera U. The story of GBD 2010: a “super-human” effort. Lancet. 2013;380:20672070.
  • 3
    Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380:22242260.
  • 4
    Dolan E, O'Brien E. Hypertension – the major cause of death and morbidity worldwide; where are our policy makers? Irish Medical Times. January 25th, 2013, page 33.
  • 5
    Nieuwlaat R, Schwalm JD, Khatib R, Yusuf S. Why are we failing to implement effective therapies in cardiovascular disease? Eur Heart J. 2013. Feb 1. [Epub ahead of print].
  • 6
    Dunbar-Jacob J, Houze MP, Kramer C, et al. Adherence to medical advice: process and measurement. In: Steptoe A, ed. Handbook of Behavioral Medicine: Methods and applications. New York: Springer, 2010, 8395.
  • 7
    Gellman MD, Turner JR eds. Encyclopedia of Behavioral Medicine. New York: Springer, 2013.
  • 8
    Howren MB. Adherence. In: Gellman MD, Turner JR eds. Encyclopedia of Behavioral Medicine. New York: Springer, 2013, 3339.
  • 9
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:25602572.
  • 10
    Chisholm-Burns MA, Spivey CA. The ‘cost’ of medication nonadherence: consequences we cannot afford to accept. J Am Pharm Assoc (2003). 2012;6:823826.
  • 11
    Parati G, Omboni S, Compare A, et al. Blood pressure control and treatment adherence in hypertensive patients with metabolic syndrome: protocol of a randomized controlled study based on home blood pressure telemonitoring vs. conventional management and assessment of psychological determinants of adherence (TELEBPMET Study). Trials. 2013;14:22. [Epub ahead of print].
  • 12
    The Script Your Future Initiative. http://scriptyourfuture.org/. Accessed January 28, 2013.
  • 13
    Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev. 2010;3:CD004371.
  • 14
    Korsch BM, Gozzi EK, Francis V. Gaps in doctor-patient communication. 1. Doctor-patient interaction and patient satisfaction. Pediatrics. 1968;42:855871.
  • 15
    Roter D, Hall JA. Doctor-patient communication: Why and how communication contributes to the quality of medical care. In: Gellman MD, Turner JR, eds. Encyclopedia of Behavioral Medicine. New York: Springer, 2013, 622627.
  • 16
    Levinson W, Lesser CS, Epstein RM. Developing physician communication skills for patient-centered care. Health Aff (Millwood). 2010;29:13101318.
  • 17
    Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement JAMA. 1999;282:14581465.
  • 18
    Cushman WC, Basile J. Achieving blood pressure goals: why aren't we? J Clin Hypertens (Greenwich). 2006;8:865872.
  • 19
    Balu S. Estimated annual direct expenditures in the United States as a result of inappropriate hypertension treatment according to national treatment guidelines. Clin Ther. 2009;31:15811594.
  • 20
    Michie S, Johnston M. Changing clinical behaviour by making guidelines specific. BMJ. 2004;328:343345.
  • 21
    Rümenapf G. Incomprehensible jargon. Dtsch Arztebl Int. 2011;108:492.
  • 22
    Redon J, Erdine S, Böhm M, et al; On behalf of the SHARE Steering Committee. Physician attitudes to blood pressure control: findings from the Supporting Hypertension Awareness and Research Europe-wide survey. J Hypertens. 2011;29:16331640.
  • 23
    Luders S, Schrader J, Schmieder RE, et al. Improvement of hypertension management by structured physician education and feedback system: cluster randomized trial. Eur J Cardiovasc Prev Rehabil. 2009;17:271279.
  • 24
    Hill MN, Miller NH, de Geest S; On behalf of the American Society of Hypertension Writing Group. ASH Position Paper: adherence and persistence with taking medication to control high blood pressure. J Clin Hypertens (Greenwich). 2010;12:757764.
  • 25
    Voogdt-Pruis HR, van Ree JW, Gorgels AP, Beusmans GH. Adherence to a guideline on cardiovascular prevention: a comparison between general practitioners and practice nurses. Int J Nurs Stud. 2011;48:798807.
  • 26
    Valderrama AL, Tong X, Ayala C, Keenan NL. Prevalence of self-reported hypertension, advice received from health care professionals, and actions taken to reduce blood pressure among US adults–HealthStyles, 2008. J Clin Hypertens (Greenwich). 2010;12:784792.
  • 27
  • 28
    Turner JR, Strumph P. The moral imperative of improving patient adherence to pharmacotherapy for cardiodiabesity, Part I: a focus on type 2 diabetes mellitus. J Patient Compliance. 2012;2(1):3236.
  • 29
    Richards AL, Turner JR. The moral imperative of improving patient adherence to pharmacotherapy for cardiodiabesity, Part II: a focus on cardiovascular disease. J Patient Compliance. 2012;2(2):3641.
  • 30
    Society for Behavioral Medicine. http://www.sbm.org/. Accessed February 26, 2013.
  • 31
    Society for Behavioral Medicine. http://www.sbm.org/publications. Accessed February 26, 2013.
  • 32
    Script Your Future Initiative. http://www.scriptyourfuture.org/wp-content/themes/cons/m/SYF_PressRelease_FINAL.pdf. Accessed February 26, 2013.
  • 33
  • 34
    American Medical Association. http://www.ama-assn.org/. Accessed February 28, 2013.
  • 35
    American Association of Colleges of Pharmacy. http://www.aacp.org/. Accessed February 28, 2013.
  • 36
    Medication Adherence Team Challenge. http://syfadherencechallenge.ning.com. Accessed February 26, 2013.
  • 37
    Armario P, Waeber B. Therapeutic strategies to improve control of hypertension. J Hypertens. 2013;31(Suppl 1):S9S12.
  • 38
    Huan Y, Townsend R. The single pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide in the treatment of hypertension. Expert Opin Pharmacother. 2012;13:24092415.
  • 39
    Kumagai N, Onishi K, Hoshino K, et al. Improving drug adherence using fixed combinations caused beneficial treatment outcomes and decreased health-care costs in patients with hypertension. Clin Exp Hypertens. 2012. Oct 16. [Epub ahead of print].
  • 40
    Panjabi S, Lacey M, Bancroft T, Cao F. Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patients. J Am Soc Hypertens. 2013;7:4660.
  • 41
    Tocci G, Paneni F, Passerini J, Volpe M. Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy. Expert Opin Pharmacother. 2012;13:26872697.
  • 42
    Volpe M, Tocci G. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic. Vasc Health Risk Manag. 2012;8:371380.
  • 43
    Dolan E, O'Brien E. Blood pressure variability: clarity for clinical practice. Hypertension. 2010;56:179181.
  • 44
    Gindlesberger DR. Office-based nursing staff management of hypertension in primary care. WMJ. 2012;111:183184.
  • 45
    Hegney DG, Patterson E, Eley DS, et al. The feasibility, acceptability and sustainability of nurse-led chronic disease management in Australian general practice: the perspectives of key stakeholders. Int J Nurs Pract. 2013;19:5459.
  • 46
    Allen JK, Dennison-Himmelfarb CR, Szanton SL, et al. Community Outreach and Cardiovascular Health (COACH) Trial: a randomized, controlled trial of nurse practitioner/community health worker cardiovascular disease risk reduction in urban community health centers. Circ Cardiovasc Qual Outcomes. 2011;4:595602.
  • 47
    Johnson W, Shaya FT, Khanna N, et al. The Baltimore Partnership to Educate and Achieve Control of Hypertension (The BPTEACH Trial): a randomized trial of the effect of education on improving blood pressure control in a largely African American population. J Clin Hypertens (Greenwich). 2011;13:563570.
  • 48
    Moran B, Walsh T. Cardiovascular disease in women: how nurses can promote awareness and prevention. Nurs Womens Health. 2013;17:6368.
  • 49
    Chang AK, Fritschi C, Kim MJ. Nurse-led empowerment strategies for hypertensive patients with metabolic syndrome. Contemp Nurse. 2012;42:118128.
  • 50
    Drevenhorn E, Bengtson A, Nilsson PM, et al. Consultation training of nurses for cardiovascular prevention - a randomized study of 2 years duration. Blood Press. 2012;21:293299.
  • 51
    Chua SS, Kok LC, Yusof FA, et al. Pharmaceutical care issues identified by pharmacists in patients with diabetes, hypertension or hyperlipidaemia in primary care settings. BMC Health Serv Res. 2012;12:388.
  • 52
    Kirschner K, Braspenning J, Jacobs JE, Grol R. Design choices made by target users for a pay-for-performance program in primary care: an action research approach. BMC Fam Pract. 2012;13:25.
  • 53
    Lee TH, Ferris TG. Pay for performance: a work in progress. Circulation. 2009;119:29652966.
  • 54
    McDonald R, Roland M. Pay for performance in primary care in England and California: comparison of unintended consequences. Ann Fam Med. 2009;7:121127.
  • 55
    Petersen LA, Urech T, Simpson K, et al. Design, rationale, and baseline characteristics of a cluster randomized controlled trial of pay for performance for hypertension treatment: study protocol. Implement Sci. 2011;6:114.
  • 56
    Petersen LA, Woodard LD, Henderson LM, et al. Will hypertension performance measures used for pay-for-performance programs penalize those who care for medically complex patients? Circulation. 2009;119:29782985.
  • 57
    Serumaga B, Ross-Degnan D, Avery AJ, et al. Effect of pay for performance on the management and outcomes of hypertension in the United Kingdom: interrupted time series study. BMJ. 2011;342:d108.
  • 58
    Scott A, Sivey P, Ait OD, et al. The effect of financial incentives on the quality of health care provided by primary care physicians. Cochrane Database Syst Rev. 2011;9:CD008451.
  • 59
    Ryan AM, Doran T. The effect of improving processes of care on patient outcomes: evidence from the United Kingdom's quality and outcomes framework. Med Care. 2012;50:191199.
  • 60
    Koenigsfeld CF, Horning KK, Logemann CD, Schmidt GA. Medication therapy management in the primary care setting: a pharmacist-based pay-for-performance project. J Pharm Pract. 2012;25:8995.
  • 61
    Long JA, Helweg-Larsen M, Volpp KG. Patient opinions regarding ‘pay for performance for patients’. J Gen Intern Med. 2008;23:16471652.
  • 62
    Wu J. Rewarding healthy behaviors–pay patients for performance. Ann Fam Med. 2012;10:261263.
  • 63
    Chernew ME, Rosen AB, Fendrick AM. Value-based insurance design. Health Aff (Millwood). 2007;26:w195w203.
  • 64
    Farley JF, Wansink D, Lindquist JH, et al. Medication adherence changes following value-based insurance design. Am J Manag Care. 2012;18:265274.
  • 65
    Frank MB, Fendrick AM, He Y, et al. The effect of a large regional health plan's value-based insurance design program on statin use. Med Care. 2012;50:934939.
  • 66
    Kim YA, Loucks A, Yokoyama G, et al. Evaluation of value-based insurance design with a large retail employer. Am J Manag Care. 2011;17:682690.
  • 67
    Chernew ME, Juster IA, Shah M, et al. Evidence that value-based insurance can be effective. Health Aff (Millwood). 2010;29:530536.
  • 68
    Choudhry NK, Avorn J, Glynn RJ, et al; Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) Trial. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365:20882097.
  • 69
    Choudhry NK, Fischer MA, Avorn JL, et al. The impact of reducing cardiovascular medication copayments on health spending and resource utilization. J Am Coll Cardiol. 2012;60:18171824.
  • 70
    Volpp KG, Loewenstein G, Asch DA. Assessing value in health care programs. JAMA. 2012;307:21532154.